{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:58:40Z","timestamp":1773683920518,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung adenosquamous carcinoma (ASC) is an uncommon histological subtype. We aimed to characterize the tumor immune microenvironment (TIME) in lung ASC and estimate patient response to immune checkpoint inhibitors (ICIs), which have never been systematically investigated. In cohort I, we collected 30 ASCs from a single center for analysis of TIME characteristics, including immuno-phenotyping, tumor mutation burden (TMB), T-cell receptor (TCR) repertoires, tumor-infiltrating lymphocytes (TILs), and immune checkpoint expression. Twenty-two (73.3%) patients were EGFR-positive. The TIME was defined by immune-excluded (60%) and immune-desert phenotype (40%). Strikingly, programmed cell death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) were predominantly expressed in squamous cell carcinoma components (SCCCs) versus adenocarcinoma components (ACCs), where enhanced CD4<jats:sup>+<\/jats:sup> FOXP3<jats:sup>+<\/jats:sup> regulatory T cell and attenuated CD57<jats:sup>+<\/jats:sup> natural killer cell infiltration were present, consistent with a landscape of fewer innate immune cells, more immunosuppressive cells. SCCCs had higher TMB, higher TCR clonality, and lower TCR diversity than ACC. In cohort III, the efficacy of ICI-based therapy was estimated using a real-world data of 46 ASCs from 11 centers. Majority of 46 patients were driver genes negative and unknown mutation status, 18 (39%) and 18 (39%), respectively. The overall objective response rate of 28%, median progression-free survival of 6.0 months (95% confidence interval [CI] 4.3\u20137.7), and median overall survival of 24.7 months (95% CI 7.2\u201342.2) were observed in the ICI-based treatment. This work ascertains suppressive TIME in lung ASC and genetic and immuno-heterogeneity between ACCs and SCCCs. Lung ASC patients have a moderate response to ICI-based immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.944812","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:25:26Z","timestamp":1660289126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Chao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pansong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S164574","article-title":"Adenosquamous carcinoma of the lung","volume":"11","author":"Li","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2014.06.004","article-title":"Adenosquamous carcinoma","volume":"31","author":"Rao","year":"2014","journal-title":"Semin Diagn Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2012.12.037","article-title":"Adenosquamous carcinoma of the lung: Surgical management, pathologic characteristics, and prognostic implications","volume":"95","author":"Mordant","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2011.05.050","article-title":"Adenosquamous carcinoma of the lung: Surgical results as compared with squamous cell and adenocarcinoma cases","volume":"41","author":"Maeda","year":"2012","journal-title":"Eur J Cardio-thoracic Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.01.030","article-title":"Adenosquamous lung carcinomas: A histologic subtype with poor prognosis","volume":"74","author":"Filosso","year":"2011","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.158","article-title":"Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung","volume":"26","author":"Shu","year":"2013","journal-title":"Modern Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.003","article-title":"Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung","volume":"55","author":"Sasaki","year":"2007","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22413","article-title":"Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung","volume":"109","author":"Kang","year":"2007","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP08IQZAOGYLFL","article-title":"Adenosquamous carcinoma of the lung: A microdissection study of KRAS and EGFR mutational and amplification status in a Western patient population","volume":"135","author":"Tochigi","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.014","article-title":"Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46209","DOI":"10.1038\/srep46209","article-title":"PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer","volume":"7","author":"Shi","year":"2017","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3440","article-title":"The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis","volume":"9","author":"Troiano","year":"2020","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","article-title":"Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer","volume":"9","author":"Jia","year":"2018","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: Software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701262","article-title":"Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment","volume":"200","author":"Gorris","year":"2018","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.013","article-title":"Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing","volume":"150","author":"Krause","year":"2020","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meeting"},{"key":"B23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2654","article-title":"Coordination of intratumoral immune reaction and human colorectal cancer recurrence","volume":"69","author":"Camus","year":"2009","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet (London England)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.02.008","article-title":"Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma","volume":"19","author":"Liu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.10.006","article-title":"PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component","volume":"214","author":"Tanigawa","year":"2018","journal-title":"Pathol Res Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.10.005","article-title":"Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: A case report and literature review","volume":"19","author":"Izumi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:25:28Z","timestamp":1660289128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.944812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.944812"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.944812","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"944812"}}